Aurora Therapeutics Launches to Scale Personalized CRISPR Gene Editing for Rare Diseases

January 09, 2026-Aurora Therapeutics officially launched with the goal of transforming personalized gene editing from single-patient breakthroughs into a scalable development model capable of reaching millions of patients with rare genetic diseases. The company debuted with a $16 million seed financing from Menlo Ventures.

Founded by CRISPR pioneers Jennifer Doudna, Ph.D., and Fyodor Urnov, Ph.D., Aurora is building a platform designed to rapidly develop and commercialize therapies tailored to rare and previously intractable genetic variants. The company was incubated by Menlo Ventures and is led by an experienced management team under Chief Executive Officer Edward M. Kaye, M.D.

Aurora’s approach combines modular gene-editing technologies, AI-enabled editor design, and purpose-built regulatory and CMC strategies to enable parallel development of multiple mutation-specific therapies. By leveraging emerging regulatory frameworks that allow grouping of multiple variants under unified development pathways, Aurora aims to make personalized gene-editing therapies economically and operationally viable at scale.

The company’s initial program focuses on phenylketonuria (PKU), a metabolic disorder caused by numerous mutations in the PAH gene. PKU represents a high unmet medical need and aligns with the FDA’s recently introduced plausible mechanism regulatory pathway. Aurora plans to design therapies capable of addressing multiple PKU-causing mutations from the outset, with expansion to additional rare diseases over time.

Aurora’s leadership team and board bring deep expertise in rare disease drug development, gene editing, manufacturing, and regulatory strategy, positioning the company to advance a new paradigm for scalable personalized genetic medicines.